Conditions: Advanced Pancreatic Ductal Adenocarcinoma; Stage II Pancreatic Cancer AJCC v8; Stage IIA Pancreatic Cancer AJCC v8; Stage IIB Pancreatic Cancer AJCC v8; Stage III Pancreatic Cancer AJCC v8; Stage IV Pancreatic Cancer AJCC v8; Unresectable Pancreatic Ductal Adenocarcinoma
Interventions: Drug: Lenvatinib Mesylate; Biological: Pembrolizumab
Sponsors: City of Hope Medical Center; National Cancer Institute (NCI)
**RECRUITING NOW**
Interventions: Drug: Lenvatinib Mesylate; Biological: Pembrolizumab
Sponsors: City of Hope Medical Center; National Cancer Institute (NCI)
**RECRUITING NOW**
Source: View full study details on ClinicalTrials.gov
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. By listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
